Background: Myxomatous mitral valve disease (MMVD) is the most common acquired cardiovascular disease in small breed dogs. In contrast to human patients with heart failure (HF), iron deficiency (ID) prevalence in dogs with MMVD is weakly known. The study aimed to assess the usability of ID markers in serum and reticulocyte parameters from whole blood of dogs with MMVD to evaluate early ID symptoms.
Results: Sixty-eight dogs (43 male and 25 female) were included in the study. MMVD dogs were assigned according to the 2019 ACVIM guidelines for groups B1 (n = 9), B2 (n = 10), C (n = 27) and D (n = 10). Groups were also combined into B1 and B2 as non-symptomatic HF and C with D as symptomatic HF. Healthy controls were 12 dogs. Serum iron concentration below the reference range in dogs with MMVD was 12.5%. Other ID indices, such as %SAT, UIBC, and TIBC were similar in the MMVD groups and healthy controls (p > 0.05 for all parameters). Statistical comparison between control group and 4 groups of different stages of MMVD showed that significant differences occur only in serum transferrin. The assessment of ferritin and soluble transferrin receptors using Western Blotting did not show differences between control (n = 7) and MMVD (n = 33) dogs. Study has shown positive correlation between ID parameters and echocardiographic indices such as LA/Ao and LVIDdN, and some biochemical parameters. A significant increase in reticulocytes percentage, assessed manually, was observed in the HF group of animals (p = 0.027) compared to the control group.
Conclusions: Studies have shown that ID parameters in serum are not significantly different in dogs with MMVD compared to healthy dogs. However, there is a clear correlation between atrial size and normalised left ventricular size to body size and some biochemical parameters, including ID parameters and therefore the severity of MMVD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11102178 | PMC |
http://dx.doi.org/10.1186/s12917-024-04071-2 | DOI Listing |
Vet Sci
November 2024
Department of Small Animal Clinical Science, School of Veterinary Science, University of Liverpool, Cardiology Service, Small Animal Teaching Hospital, Chester High Road, Neston CH64 7TE, UK.
The present study aimed to evaluate the effects of chronic pimobendan monotherapy on cardiac size in dogs with stage B2 myxomatous mitral valve disease (MMVD). Data from 31 dogs diagnosed with MMVD and cardiomegaly (LA/Ao ≥ 1.6 and LVIDdn ≥ 1.
View Article and Find Full Text PDFSchweiz Arch Tierheilkd
December 2024
Division of Cardiology, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich.
Open Vet J
September 2024
Prasu Arthorn Veterinary Teaching Hospital, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
Background: Myxomatous mitral valve degeneration (MMVD) is a prevalent canine heart condition often accompanied by pulmonary hypertension (PH). Echocardiography is a valuable diagnostic tool for MMVD, but its accessibility is limited in small veterinary clinics.
Aim: This study aimed to identify clinical parameters and biochemistry and cardiac biomarkers as prognostic indicators for cardiac mortality in MMVD dogs with and without PH.
Front Vet Sci
November 2024
Department of Small Animal Clinical Science, School of Veterinary Science, Leahurst Campus, University of Liverpool, Neston, United Kingdom.
Background: Myxomatous mitral valve disease (MMVD) is a common, acquired, and progressive canine heart disease. The presence of heart murmur and current cardiac biomarkers are useful in MMVD cases but are not sufficiently discriminatory for staging an individual patient.
Objectives: This study aimed to conduct a preliminary assessment of canine serum and plasma expression profiles of 15 selected miRNA markers for accurate discrimination between MMVD patients and healthy controls.
Vet Radiol Ultrasound
January 2025
Laboratory of Veterinary Small Animal Internal Medicine, Cooperative Department of Veterinary Medicine, Faculty of Agriculture, Iwate University, Morioka, Japan.
Since the prognosis of myxomatous mitral valve disease (MMVD) varies, its characterization is clinically relevant, and renal impairment has been identified as one of its associated factors. Intrarenal Doppler ultrasonography (IRD), an intrarenal hemodynamic assessment method, is useful for predicting cardiac- and renal-related death but cannot detect early changes in dogs with preclinical MMVD. Contrast-enhanced ultrasonography (CEUS), another intrarenal hemodynamic assessment method, may identify earlier changes; however, renal perfusion evaluations using CEUS have not yet been performed on dogs with MMVD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!